KRAS

Across TCGA pan-cancer cohorts, KRAS Mutation is linked to patient survival in 14 of 34 cancer types, making it a survival-associated KRAS data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher KRAS Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KRAS expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, LUSC, and UCEC are the cancer types where KRAS Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.183	0.553	<.001	40	view →
LUSC	DFS	Median	All	0.079	0.792	<.001	33	view →
UCEC	DFS	Median	III,IV	0.885	0.500	.005	26	view →
LUAD	DFS	Median	III,IV	0.391	0.770	<.001	23	view →
DLBC	OS	Median	All	0.054	0.842	<.001	12	view →
SARC	OS	Median	All	0.164	0.839	<.001	12	view →
MESO	OS	Median	All	0.018	0.559	<.001	12	view →
LIHC	DFS	Median	III,IV	0.079	0.333	.009	12	view →
SKCM	DFS	Median	III,IV	0.160	0.615	.015	7	view →
TGCT	OS	Median	All	0.771	0.968	.006	6	view →
GBM	DFS	Median	All	0.071	0.288	.009	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 14 lineages.

KRAS–BLCA (OS)

Open the BLCA breakdown →